Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Agrylin (anagrelide)
- deferasirox
Interactions between your drugs
anagrelide deferasirox
Applies to: Agrylin (anagrelide), deferasirox
Using deferasirox together with anagrelide may increase the risk of gastrointestinal ulcers and bleeding. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should seek immediate medical attention if you experience potential signs and symptoms of gastrointestinal injury such as abdominal pain, bloating, dizziness, lightheadedness, loss of appetite, nausea, vomiting (especially with fresh or dried blood that looks like coffee grounds), and red or black, tarry stools. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
deferasirox food
Applies to: deferasirox
You may experience reduced absorption of deferasirox in the presence of food. Take deferasirox on an empty stomach 30 minutes before eating preferably at the same time everyday unless otherwise directed by your doctor. This will make it easier for your body to absorb the medication. The tablets should not be chewed or swallowed whole. The tablets should first be completely dispersed in water, orange juice, or apple juice, and the resulting suspension drunk immediately. After swallowing the suspension any residue should be resuspended in a small volume of the liquid and swallowed.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
PegIntron
PegIntron is used to treat chronic hepatitis C in adults. Learn about side effects, interactions ...
Sylatron
Sylatron (peginterferon alfa-2b) used to prevent malignant melanoma from coming back after it has ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Advate
Advate (antihemophilic factor) is used to prevent bleeding episodes in adults and children with ...
Adzynma
Adzynma (ADAMTS13, recombinant-krhn) is a human recombinant protein that may be used to prevent or ...
Alhemo
Alhemo is used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in ...
Alphanine SD
Alphanine SD is used for factor ix deficiency, hemophilia b
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.